Journal article
Subsequent Primary Malignancies in Patients with Indolent B Cell Non-Hodgkin Lymphoma Receiving Frontline Bendamustine Rituximab Therapy
Abstract
Introduction: Bendamustine is used in combination with rituximab (BR) for frontline treatment of indolent non-Hodgkin lymphoma (iNHL). BR was publicly funded in Ontario, Canada in 2013. Though patients often experience prolonged treatment free survival after therapy, patient burden can result from infections and toxicities including subsequent primary malignancy (SPM). Reported cumulative incidence of SPM ranges from 3-18% over 3-9 years, …
Authors
Davies GA; Prica A; Ante Z; Liu N; Pond GR; Balitsky AK; Mozessohn L
Journal
Blood, Vol. 144, No. Supplement 1, pp. 3749–3749
Publisher
American Society of Hematology
Publication Date
November 5, 2024
DOI
10.1182/blood-2024-211926
ISSN
0006-4971